CA2962255A1 - Use of annexin v as a method to block tumor induced immunosuppression of the innate immune response - Google Patents

Use of annexin v as a method to block tumor induced immunosuppression of the innate immune response Download PDF

Info

Publication number
CA2962255A1
CA2962255A1 CA2962255A CA2962255A CA2962255A1 CA 2962255 A1 CA2962255 A1 CA 2962255A1 CA 2962255 A CA2962255 A CA 2962255A CA 2962255 A CA2962255 A CA 2962255A CA 2962255 A1 CA2962255 A1 CA 2962255A1
Authority
CA
Canada
Prior art keywords
cancer
annexin
tumor
cells
agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2962255A
Other languages
English (en)
French (fr)
Inventor
Francis Gerard BLANKENBERG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Publication of CA2962255A1 publication Critical patent/CA2962255A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CA2962255A 2014-10-03 2015-10-02 Use of annexin v as a method to block tumor induced immunosuppression of the innate immune response Abandoned CA2962255A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462059669P 2014-10-03 2014-10-03
US62/059,669 2014-10-03
PCT/US2015/053828 WO2016054574A1 (en) 2014-10-03 2015-10-02 Use of annexin v as a method to block tumor induced immunosuppression of the innate immune response

Publications (1)

Publication Number Publication Date
CA2962255A1 true CA2962255A1 (en) 2016-04-07

Family

ID=55631651

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2962255A Abandoned CA2962255A1 (en) 2014-10-03 2015-10-02 Use of annexin v as a method to block tumor induced immunosuppression of the innate immune response

Country Status (7)

Country Link
US (2) US11253568B2 (enExample)
EP (1) EP3200811A4 (enExample)
JP (1) JP2017530130A (enExample)
KR (1) KR20170063722A (enExample)
AU (1) AU2015327887A1 (enExample)
CA (1) CA2962255A1 (enExample)
WO (1) WO2016054574A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG175992A1 (en) 2009-05-11 2011-12-29 Berg Biosystems Llc Methods for treatment of disease using an epimetabolic shifter (coenzyme q10)
CA2832324C (en) 2011-04-04 2022-03-15 Berg Llc Methods of treating central nervous system tumors
BR112015025424A2 (pt) 2013-04-08 2017-07-18 Berg Llc tratamento de câncer usando terapias de combinação de coenzima q10
KR102370843B1 (ko) 2013-09-04 2022-03-04 버그 엘엘씨 코엔자임 q10의 연속주입에 의한 암치료 방법
KR20170063722A (ko) * 2014-10-03 2017-06-08 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 선천적 면역 반응의 종양 유도된 면역억제를 차단하기 위한 방법으로서의 아넥신 v의 사용
WO2017087576A1 (en) 2015-11-16 2017-05-26 Berg Llc Methods of treatment of temozolomide-resistant glioma using coenzyme q10
US20180021270A1 (en) * 2016-07-21 2018-01-25 Berg Llc Methods for the treatment of cancer using coenzyme q10 in combination with immune checkpoint modulators
WO2019010181A1 (en) * 2017-07-05 2019-01-10 The Board Of Trustees Of The Leland Stanford Junior University USE OF ANNEXIN V TO REDUCE THE PROPAGATION OF INTRACELLULAR PATHOGENIC AGENTS
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
CA3180886A1 (en) * 2020-07-09 2022-01-13 Cheng Luo Compositions and methods for inhibiting ythdf1
WO2022212352A1 (en) * 2021-03-29 2022-10-06 The Board Of Trustees Of The Leland Stanford Junior University Reversal of ctl exhaustion with annexin v
WO2023130112A1 (en) * 2022-01-03 2023-07-06 The Board Of Trustees Of The Leland Stanford Junior University Blocking and reversing extracellular vesicle driven transcriptomic transformation with annexin v treatment

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7262167B2 (en) * 1995-11-06 2007-08-28 Exibona Ltd. Drug, in particular for modulating the immunological response for the control of viruses, tumors, bacteria and parasites
US6818213B1 (en) * 1998-07-13 2004-11-16 Board Of Regents, The University Of Texas System Cancer treatment compositions comprising therapeutic conjugates that bind to aminophospholipids
US7635680B2 (en) 2001-02-21 2009-12-22 Alavita Pharmaceuticals, Inc. Attenuation of reperfusion injury
JP2004529922A (ja) * 2001-04-03 2004-09-30 ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ 生体内における細胞死の画像化の方法
DE10145254A1 (de) * 2001-09-13 2003-04-10 November Ag Molekulare Medizin Verwendung eines Proteins zur Herstellung eines Medikaments zur Stimulierung einer inflammatorischen zellulären Immunantwort
DE10302422A1 (de) * 2003-01-21 2004-07-29 Responsif Gmbh Medikament und Verwendung zur Tumortherapie
US8071545B2 (en) * 2005-03-15 2011-12-06 Lewis S. Coleman, Md, Inc. Therapies and compositions for controlling the stress mechanism and for stabilizing hemostasis in an organism
GB0911042D0 (en) 2009-06-25 2009-08-12 Istituto Superiore Di Sanito Treatment of tumorigenic cells in solid tumours
KR20170063722A (ko) * 2014-10-03 2017-06-08 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 선천적 면역 반응의 종양 유도된 면역억제를 차단하기 위한 방법으로서의 아넥신 v의 사용

Also Published As

Publication number Publication date
KR20170063722A (ko) 2017-06-08
JP2017530130A (ja) 2017-10-12
US20220160829A1 (en) 2022-05-26
US20170202914A1 (en) 2017-07-20
EP3200811A1 (en) 2017-08-09
WO2016054574A1 (en) 2016-04-07
US12508296B2 (en) 2025-12-30
US11253568B2 (en) 2022-02-22
EP3200811A4 (en) 2018-05-02
AU2015327887A1 (en) 2017-04-13

Similar Documents

Publication Publication Date Title
US12508296B2 (en) Use of annexin V as a method to block tumor induced immunosuppression of the innate immune response
ES3006183T3 (en) Antibody molecules that bind pd-l1 and cd137
US20210338701A1 (en) Dna hypomethylating agents for cancer therapy
ES2808153T3 (es) Terapia de combinación para tratamiento de enfermedad
JP6240600B2 (ja) ヒト化免疫モノクローナル抗体の変異体
KR101839864B1 (ko) 암을 치료하는 방법
JP2025081512A (ja) 血液がんおよび固形がんの治療のためのキメラ抗原受容体改変ｔ細胞（ｃａｒ－ｔ）
ES2978486T3 (es) Métodos para promover la respuesta de linfocitos T
KR20180023968A (ko) 혈액암 및 충실성 종양의 치료를 위한 병용 요법
WO2009147781A1 (ja) 抗がん剤
CA3196651A1 (en) Nanoparticle complex with defined sizes
KR102239752B1 (ko) 종양 특이적 약물복합체와 항pd-l1 항체를 유효성분으로 하는 암 예방 또는 치료를 위한 병용 투여용 약학 조성물
US20250049884A1 (en) Blocking and reversing extracellular vesicle driven transcriptomic transformation with annexin v treatment
RU2801828C2 (ru) Комбинированная терапия блокированием семафорина 4d (sema4d) и терапией дк1
US20220387441A1 (en) Targeting the neuroligin-3 binding partner cspg4 in glioma
JP4686733B2 (ja) 抗がん剤
US20220047701A1 (en) Combination of her2/neu antibody with heme for treating cancer
HK40121706A (zh) Car-t细胞的原位募集、重编程与释放
TW202542201A (zh) 抗psma軛合物及其使用方法
TW202539732A (zh) 以雙特異性抗muc16×抗cd28抗體與抗pd-1抗體之組合或與雙特異性抗muc16×抗cd3抗體之組合治療復發性卵巢癌及子宮內膜癌之方法
WO2009147695A1 (ja) 抗がん剤
KR20200014769A (ko) 항체 가변 도메인 및 항체 구조물
JP2011074093A (ja) 抗がん剤

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20201002